National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 62189-62190 [2021-24443]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 214 / Tuesday, November 9, 2021 / Notices
Disorder Relevant Pathways (R01—Clinical
Trials Not Allowed).
Date: January 24, 2022.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Soyoun Cho, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, Bethesda, MD
20892, (301) 594–9460, Soyoun.cho@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24444 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
jspears on DSK121TN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Understanding PostTranscriptional Regulation of Intact and
Defective HIV RNA (R61/R33 Clinical Trial
Not Allowed).
Date: November 16, 2021.
Time: 11:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G36,
Rockville, MD 20892 (Virtual Meeting).
VerDate Sep<11>2014
17:00 Nov 08, 2021
Jkt 256001
Contact Person: Poonam Pegu, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G36,
Rockville, MD 20892, 240–292–0719,
poonam.pegu@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Prevention Strategies to End
the HIV Epidemic (R01 Clinical Trial
Optional).
Date: November 18, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G21A,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Dimitrios N. Vatakis,
Ph.D., Scientific Review Officer, Scientific
Review Program, National Institute of Allergy
and Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G21A,
Rockville, MD 20892, 301–761–7176,
dimitrios.vatakis@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24442 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
62189
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Tuberculosis Research
Advancement Centers (TRACs) (P30 Clinical
Trial Not Allowed).
Date: November 10–12, 2021.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G13B,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Yong Gao, Ph.D., Scientific
Review Officer, Scientific Review Program,
Division of Extramural Activities, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3G13B, Rockville, MD 20892–
7616, (240) 669–5048, gaoL2@niaid.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24434 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Division of Intramural
Research Board of Scientific Counselors,
National Institute of Allergy and
Infectious Diseases.
The meeting will be closed to the
public as indicated below in accordance
with the provisions set forth in section
552b(c)(6), Title 5 U.S.C., as amended
for the review, discussion, and
evaluation of individual intramural
programs and projects conducted by the
National Institute of Allergy and
Infectious Diseases, including
consideration of personnel
qualifications and performance, and the
competence of individual investigators,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\09NON1.SGM
09NON1
62190
Federal Register / Vol. 86, No. 214 / Tuesday, November 9, 2021 / Notices
Name of Committee: Division of Intramural
Research Board of Scientific Counselors,
NIAID.
Date: December 13–15, 2021.
Time: 8:30 a.m. to 11:15 a.m.
Agenda: To review and evaluate personnel
qualifications and performance, and
competence of individual investigators.
Place: National Institutes of Health, 50
Center Drive, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Laurie Lewellen,
Committee Manger, Division of Intramural
Research Program Support Staff, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, Building 33,
Room 1N24, 33 North Drive, Bethesda, MD
20892, 301–761–6362, Laurie.Lewallen@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–24443 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Use of Tomentosenol
in Treating or Preventing Skin
Disorders
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive, sublicensable
patent license to University of the
Sunshine Coast (‘‘USC’’), a public
university based on the Sunshine Coast,
Queensland, Australia, in its rights to
the inventions and patents listed in the
SUPPLEMENTARY INFORMATION section of
this notice.
DATES: Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before November 24, 2021 will be
considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Rose M. Freel, Ph.D., Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, Telephone
jspears on DSK121TN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:00 Nov 08, 2021
Jkt 256001
(301) 624–8775 or Email: rose.freel@
nih.gov.
The
following and all continuing U.S. and
foreign patents/patent applications
thereof are the intellectual properties to
be licensed under the prospective
agreement to USC: Australian
Provisional Patent Application No.
2021902329, filed Aug 3, 2021, entitled
‘‘Use of tomentosenol in treating or
preventing skin disorders’’ (HHS Ref.
No. E–107–2021–0).
The patent rights in these inventions
have been assigned to the Government
of the United States of America and the
University of the Sunshine Coast. The
prospective patent license will be for
the purpose of consolidating the patent
rights to USC, one of the co-owners of
said rights, for commercial development
and marketing. Consolidation of these
co-owned rights is intended to expedite
development of the invention,
consistent with the goals of the BayhDole Act codified as 35 U.S.C. 200–212.
The prospective patent license will be
worldwide, exclusive, and may be
limited to those fields of use
commensurate in scope with the patent
rights. It will be sublicensable, and any
sublicenses granted by USC will be
subject to the provisions of 37 CFR part
401 and 404.
The invention pertains to
tomentosenol A, a natural product that
may be useful for treating, inhibiting, or
preventing scar formation development
or progression, reducing pre-existing
scar tissue, and/or other fibrotic skin
disorders. Based on current available
data, the intended use for the invention
is as a therapeutic in scar therapy, skin
fibrosis, skin diseases, and inhibition of
the proliferation or migration of skin
cells.
This notice is made pursuant to 35
U.S.C. 209 and 37 CFR part 404. The
prospective exclusive patent license
will include terms for the sharing of
royalty income with NCI from
commercial sublicenses of the patent
rights and may be granted unless within
fifteen (15) days from the date of this
published notice the NCI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license
that are timely filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
patent license. In response to this
Notice, the public may file comments or
objections. Comments and objections,
other than those in the form of a license
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information from these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 3, 2021.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2021–24445 Filed 11–8–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Regents of the
National Library of Medicine.
The meeting will be open to the
public as indicated below. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Board of Regents of
the National Library of Medicine.
Date: February 8, 2022.
Open: February 8, 2022, 10:00 a.m. to 3:30
p.m.
Agenda: Program Discussion.
Place: Virtual Meeting.
Closed: February 8, 2022, 3:30 p.m. to 4:00
p.m.
Agenda: To review and evaluate grant
applications.
Contact Person: Christine Ireland,
Committee Management Officer, Division of
Extramural Programs, National Library of
Medicine, 6705 Rockledge Drive, Suite 500,
Bethesda, MD 20892, 301–594–4929,
irelanc@mail.nih.gov.
E:\FR\FM\09NON1.SGM
09NON1
]]>Agencies
[Federal Register Volume 86, Number 214 (Tuesday, November 9, 2021)]
[Notices]
[Pages 62189-62190]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-24443]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Division of
Intramural Research Board of Scientific Counselors, National Institute
of Allergy and Infectious Diseases.
The meeting will be closed to the public as indicated below in
accordance with the provisions set forth in section 552b(c)(6), Title 5
U.S.C., as amended for the review, discussion, and evaluation of
individual intramural programs and projects conducted by the National
Institute of Allergy and Infectious Diseases, including consideration
of personnel qualifications and performance, and the competence of
individual investigators, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
[[Page 62190]]
Name of Committee: Division of Intramural Research Board of
Scientific Counselors, NIAID.
Date: December 13-15, 2021.
Time: 8:30 a.m. to 11:15 a.m.
Agenda: To review and evaluate personnel qualifications and
performance, and competence of individual investigators.
Place: National Institutes of Health, 50 Center Drive, Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Laurie Lewellen, Committee Manger, Division of
Intramural Research Program Support Staff, National Institute of
Allergy and Infectious Diseases, National Institutes of Health,
Building 33, Room 1N24, 33 North Drive, Bethesda, MD 20892, 301-761-
6362, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: November 3, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-24443 Filed 11-8-21; 8:45 am]
BILLING CODE 4140-01-P
